{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T17:48:43Z","timestamp":1759600123578},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"32","license":[{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,8,10]]},"DOI":"10.1038\/onc.2017.101","type":"journal-article","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T20:15:33Z","timestamp":1491250533000},"page":"4662-4669","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Angiomotin-like 2 interacts with and negatively regulates AKT"],"prefix":"10.1038","volume":"36","author":[{"given":"H","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,3]]},"reference":[{"key":"BFonc2017101_CR1","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1101\/gad.1536007","volume":"21","author":"D Pan","year":"2007","unstructured":"Pan D . Hippo signaling in organ size control. Genes Dev 2007; 21: 886\u2013897.","journal-title":"Genes Dev"},{"key":"BFonc2017101_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrd4161","volume":"13","author":"R Johnson","year":"2014","unstructured":"Johnson R, Halder G . The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 2014; 13: 63\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"BFonc2017101_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","volume":"163","author":"FX Yu","year":"2015","unstructured":"Yu FX, Zhao B, Guan KL . Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 2015; 163: 811\u2013828.","journal-title":"Cell"},{"key":"BFonc2017101_CR4","doi-asserted-by":"publisher","first-page":"8357","DOI":"10.1038\/ncomms9357","volume":"6","author":"Z Meng","year":"2015","unstructured":"Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, Hong AW et al. MAP4K family kinases act in parallel to MST1\/2 to activate LATS1\/2 in the Hippo pathway. Nat Commun 2015; 6: 8357.","journal-title":"Nat Commun"},{"key":"BFonc2017101_CR5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1073\/pnas.0911427107","volume":"107","author":"L Lu","year":"2010","unstructured":"Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 2010; 107: 1437\u20131442.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017101_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2009.09.026","volume":"16","author":"D Zhou","year":"2009","unstructured":"Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009; 16: 425\u2013438.","journal-title":"Cancer Cell"},{"key":"BFonc2017101_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.devcel.2010.06.015","volume":"19","author":"N Zhang","year":"2010","unstructured":"Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J et al. The Merlin\/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010; 19: 27\u201338.","journal-title":"Dev Cell"},{"key":"BFonc2017101_CR8","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.cub.2007.10.039","volume":"17","author":"FD Camargo","year":"2007","unstructured":"Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007; 17: 2054\u20132060.","journal-title":"Curr Biol"},{"key":"BFonc2017101_CR9","doi-asserted-by":"publisher","first-page":"E71","DOI":"10.1073\/pnas.1517188113","volume":"113","author":"M Nishio","year":"2016","unstructured":"Nishio M, Sugimachi K, Goto H, Wang J, Morikawa T, Miyachi Y et al. Dysregulated YAP1\/TAZ and TGF-beta signaling mediate hepatocarcinogenesis in Mob1a\/1b-deficient mice. Proc Natl Acad Sci USA 2016; 113: E71\u2013E80.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017101_CR10","doi-asserted-by":"publisher","first-page":"8248","DOI":"10.1073\/pnas.0912203107","volume":"107","author":"KP Lee","year":"2010","unstructured":"Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107: 8248\u20138253.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017101_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey KF, Zhang X, Thomas DM . The Hippo pathway and human cancer. Nat Rev 2013; 13: 246\u2013257.","journal-title":"Nat Rev"},{"key":"BFonc2017101_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1101\/gad.2000111","volume":"25","author":"B Zhao","year":"2011","unstructured":"Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011; 25: 51\u201363.","journal-title":"Genes Dev"},{"key":"BFonc2017101_CR13","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1074\/jbc.C110.212621","volume":"286","author":"SW Chan","year":"2011","unstructured":"Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W . Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011; 286: 7018\u20137026.","journal-title":"J Biol Chem"},{"key":"BFonc2017101_CR14","doi-asserted-by":"publisher","first-page":"ra77","DOI":"10.1126\/scisignal.2004060","volume":"6","author":"C Yi","year":"2013","unstructured":"Yi C, Shen Z, Stemmer-Rachamimov A, Dawany N, Troutman S, Showe LC et al. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal 2013; 6: ra77.","journal-title":"Sci Signal"},{"key":"BFonc2017101_CR15","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1091\/mbc.e11-04-0300","volume":"22","author":"M Paramasivam","year":"2011","unstructured":"Paramasivam M, Sarkeshik A, Yates JR III, Fernandes MJ, McCollum D . Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol Biol Cell 2011; 22: 3725\u20133733.","journal-title":"Mol Biol Cell"},{"key":"BFonc2017101_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.15252\/embr.201540809","volume":"17","author":"M Kim","year":"2016","unstructured":"Kim M, Kim M, Park SJ, Lee C, Lim DS . Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition. EMBO Rep 2016; 17: 64\u201378.","journal-title":"EMBO Rep"},{"key":"BFonc2017101_CR17","doi-asserted-by":"publisher","first-page":"17368","DOI":"10.1073\/pnas.1308236110","volume":"110","author":"JJ Adler","year":"2013","unstructured":"Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1\/2 protein kinases. Proc Natl Acad Sci USA 2013; 110: 17368\u201317373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017101_CR18","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1074\/jbc.C110.205401","volume":"286","author":"W Wang","year":"2011","unstructured":"Wang W, Huang J, Chen J . Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem 2011; 286: 4364\u20134370.","journal-title":"J Biol Chem"},{"key":"BFonc2017101_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/cr.2015.69","volume":"25","author":"Y Li","year":"2015","unstructured":"Li Y, Zhou H, Li F, Chan SW, Lin Z, Wei Z et al. Angiomotin binding-induced activation of Merlin\/NF2 in the Hippo pathway. Cell Res 2015; 25: 801\u2013817.","journal-title":"Cell Res"},{"key":"BFonc2017101_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.celrep.2015.09.014","volume":"13","author":"W Wang","year":"2015","unstructured":"Wang W, Li N, Li X, Tran MK, Han X, Chen J . Tankyrase inhibitors target YAP by stabilizing Angiomotin family proteins. Cell Rep 2015; 13: 524\u2013532.","journal-title":"Cell Rep"},{"key":"BFonc2017101_CR21","doi-asserted-by":"publisher","first-page":"15256","DOI":"10.1074\/jbc.M116.722967","volume":"291","author":"H Wang","year":"2016","unstructured":"Wang H, Lu B, Castillo J, Zhang Y, Yang Z, McAllister G et al. Tankyrase inhibitor sensitizes lung cancer cells to endothelial growth factor receptor (EGFR) inhibition via stabilizing Angiomotins and inhibiting YAP signaling. J Biol Chem 2016; 291: 15256\u201315266.","journal-title":"J Biol Chem"},{"key":"BFonc2017101_CR22","doi-asserted-by":"publisher","first-page":"28765","DOI":"10.18632\/oncotarget.9117","volume":"7","author":"A Troilo","year":"2016","unstructured":"Troilo A, Benson EK, Esposito D, Garibsingh RA, Reddy EP, Mungamuri SK et al. Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. Oncotarget 2016; 7: 28765\u201328782.","journal-title":"Oncotarget"},{"key":"BFonc2017101_CR23","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/ncomms3251","volume":"4","author":"CY Leung","year":"2013","unstructured":"Leung CY, Zernicka-Goetz M . Angiomotin prevents pluripotent lineage differentiation in mouse embryos via Hippo pathway-dependent and -independent mechanisms. Nat Commun 2013; 4: 2251.","journal-title":"Nat Commun"},{"key":"BFonc2017101_CR24","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.cub.2013.05.014","volume":"23","author":"Y Hirate","year":"2013","unstructured":"Hirate Y, Hirahara S, Inoue K, Suzuki A, Alarcon VB, Akimoto K et al. Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos. Curr Biol 2013; 23: 1181\u20131194.","journal-title":"Curr Biol"},{"key":"BFonc2017101_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ccr.2011.02.017","volume":"19","author":"C Yi","year":"2011","unstructured":"Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 2011; 19: 527\u2013540.","journal-title":"Cancer Cell"},{"key":"BFonc2017101_CR26","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1101\/gad.432007","volume":"21","author":"K Aase","year":"2007","unstructured":"Aase K, Ernkvist M, Ebarasi L, Jakobsson L, Majumdar A, Yi C et al. Angiomotin regulates endothelial cell migration during embryonic angiogenesis. Genes Dev 2007; 21: 2055\u20132068.","journal-title":"Genes Dev"},{"key":"BFonc2017101_CR27","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1038\/ncomms5557","volume":"5","author":"M Mojallal","year":"2014","unstructured":"Mojallal M, Zheng Y, Hultin S, Audebert S, van Harn T, Johnsson P et al. AmotL2 disrupts apical-basal cell polarity and promotes tumour invasion. Nat Commun 2014; 5: 4557.","journal-title":"Nat Commun"},{"key":"BFonc2017101_CR28","doi-asserted-by":"crossref","first-page":"12393","DOI":"10.18632\/oncotarget.7161","volume":"7","author":"M Lv","year":"2016","unstructured":"Lv M, Li S, Luo C, Zhang X, Shen Y, Sui YX et al. Angiomotin promotes renal epithelial and carcinoma cell proliferation by retaining the nuclear YAP. Oncotarget 2016; 7: 12393\u201312403.","journal-title":"Oncotarget"},{"key":"BFonc2017101_CR29","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1016\/j.febslet.2014.02.006","volume":"588","author":"S Moleirinho","year":"2014","unstructured":"Moleirinho S, Guerrant W, Kissil JL . The Angiomotins\u2014from discovery to function. FEBS Lett 2014; 588: 2693\u20132703.","journal-title":"FEBS Lett"},{"key":"BFonc2017101_CR30","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1002\/j.1460-2075.1996.tb01045.x","volume":"15","author":"DR Alessi","year":"1996","unstructured":"Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15: 6541\u20136551.","journal-title":"EMBO J"},{"key":"BFonc2017101_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL . The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev 2002; 2: 489\u2013501.","journal-title":"Nat Rev"},{"key":"BFonc2017101_CR32","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.4161\/cc.29584","volume":"13","author":"P Liu","year":"2014","unstructured":"Liu P, Wang Z, Wei W . Phosphorylation of Akt at the C-terminal tail triggers Akt activation. Cell Cycle 2014; 13: 2162\u20132164.","journal-title":"Cell Cycle"},{"key":"BFonc2017101_CR33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature13079","volume":"508","author":"P Liu","year":"2014","unstructured":"Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D et al. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature 2014; 508: 541\u2013545.","journal-title":"Nature"},{"key":"BFonc2017101_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1042\/BJ20150325","volume":"471","author":"TO Chan","year":"2015","unstructured":"Chan TO, Zhang J, Tiegs BC, Blumhof B, Yan L, Keny N et al. Akt kinase C-terminal modifications control activation loop dephosphorylation and enhance insulin response. Biochem J 2015; 471: 37\u201351.","journal-title":"Biochem J"},{"key":"BFonc2017101_CR35","doi-asserted-by":"publisher","first-page":"15789","DOI":"10.1074\/jbc.M212525200","volume":"278","author":"T Jiang","year":"2003","unstructured":"Jiang T, Qiu Y . Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem 2003; 278: 15789\u201315793.","journal-title":"J Biol Chem"},{"key":"BFonc2017101_CR36","doi-asserted-by":"publisher","first-page":"a011189","DOI":"10.1101\/cshperspect.a011189","volume":"4","author":"BA Hemmings","year":"2012","unstructured":"Hemmings BA, Restuccia DF . PI3K-PKB\/Akt pathway. Cold Spring Harb Perspect Biol 2012; 4: a011189.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"BFonc2017101_CR37","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jhep.2013.11.031","volume":"60","author":"MS Matter","year":"2014","unstructured":"Matter MS, Decaens T, Andersen JB, Thorgeirsson SS . Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 2014; 60: 855\u2013865.","journal-title":"J Hepatol"},{"key":"BFonc2017101_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","volume":"4","author":"J Luo","year":"2003","unstructured":"Luo J, Manning BD, Cantley LC . Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4: 257\u2013262.","journal-title":"Cancer Cell"},{"key":"BFonc2017101_CR39","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/ncb3113","volume":"17","author":"W Wang","year":"2015","unstructured":"Wang W, Xiao ZD, Li X, Aziz KE, Gan B, Johnson RL et al. AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat Cell Biol 2015; 17: 490\u2013499.","journal-title":"Nat Cell Biol"},{"key":"BFonc2017101_CR40","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1101\/gad.262816.115","volume":"29","author":"T Moroishi","year":"2015","unstructured":"Moroishi T, Park HW, Qin B, Chen Q, Meng Z, Plouffe SW et al. A YAP\/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Genes Dev 2015; 29: 1271\u20131284.","journal-title":"Genes Dev"},{"key":"BFonc2017101_CR41","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/cr.2015.101","volume":"25","author":"X Dai","year":"2015","unstructured":"Dai X, Liu H, Shen S, Guo X, Yan H, Ji X et al. YAP activates the Hippo pathway in a negative feedback loop. Cell Res 2015; 25: 1175\u20131178.","journal-title":"Cell Res"},{"key":"BFonc2017101_CR42","doi-asserted-by":"publisher","first-page":"34041","DOI":"10.1074\/jbc.M113.518019","volume":"288","author":"X Dai","year":"2013","unstructured":"Dai X, She P, Chi F, Feng Y, Liu H, Jin D et al. Phosphorylation of angiomotin by Lats1\/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J Biol Chem 2013; 288: 34041\u201334051.","journal-title":"J Biol Chem"},{"key":"BFonc2017101_CR43","doi-asserted-by":"publisher","first-page":"37296","DOI":"10.1074\/jbc.M113.527598","volume":"288","author":"SW Chan","year":"2013","unstructured":"Chan SW, Lim CJ, Guo F, Tan I, Leung T, Hong W . Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation. J Biol Chem 2013; 288: 37296\u201337307.","journal-title":"J Biol Chem"},{"key":"BFonc2017101_CR44","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/hep.28507","volume":"63","author":"Y Li","year":"2016","unstructured":"Li Y, Tsang CK, Wang S, Li XX, Yang Y, Fu L et al. MAF1 suppresses AKT-mTOR signaling and liver cancer through activation of PTEN transcription. Hepatology 2016; 63: 1928\u20131942.","journal-title":"Hepatology"},{"key":"BFonc2017101_CR45","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1002\/cncr.24495","volume":"115","author":"MZ Xu","year":"2009","unstructured":"Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115: 4576\u20134585.","journal-title":"Cancer"},{"key":"BFonc2017101_CR46","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1242\/jcs.018176","volume":"121","author":"W Wang","year":"2008","unstructured":"Wang W, Chen L, Ding Y, Jin J, Liao K . Centrosome separation driven by actin-microfilaments during mitosis is mediated by centrosome-associated tyrosine-phosphorylated cortactin. J Cell Sci 2008; 121: 1334\u20131343.","journal-title":"J Cell Sci"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2017101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2017101","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2017.101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/onc2017101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:19:03Z","timestamp":1647893943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2017101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,3]]},"references-count":46,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2017,8,10]]}},"alternative-id":["BFonc2017101"],"URL":"https:\/\/doi.org\/10.1038\/onc.2017.101","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,3]]},"assertion":[{"value":"3 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}